<DOC>
	<DOCNO>NCT01578772</DOCNO>
	<brief_summary>This research study see whether blood vessel function , early sign heart disease , improve HIV-infected men woman take telmisartan 12 week . The investigator look blood vessel arm , call brachial artery , change response stress take telmisartan . To determine well blood vessel function , investigator use ultrasound machine . Telmisartan HIV medication . It FDA-approved medication design treat blood pressure , show improve blood vessel function HIV-negative people without high blood pressure . Telmisartan make Boehringer Ingelheim , trial sponsor The Campbell Foundation .</brief_summary>
	<brief_title>A Clinical Trial People HIV+ Age &gt; 50 Risk Heart Disease</brief_title>
	<detailed_description />
	<mesh_term>Cardiovascular Diseases</mesh_term>
	<mesh_term>Heart Diseases</mesh_term>
	<mesh_term>Telmisartan</mesh_term>
	<criteria>HIV positive men woman &gt; 50 year age . HIV1 RNA document &lt; 50 copies/mL screen undetectable assay choice ( &lt; 50 &lt; 400 copies/mL ) least 12 week prior entry . Current ART suppressive , highly active regimen . Subjects must change ART 12 week prior entry , must plan change ART 12week study duration . Systolic blood pressure &gt; 110mmHg . One risk factor CVD ( smoking , hypertension , hyperlipidemia , diabetes mellitus ) . Note : family history early heart disease alone sufficient entry criterion . Ability willingness subject provide inform consent . Pregnancy ( current within past 6 month ) nursing . Uncontrolled hypertension : Prohibited concomitant medication : Other member angiotensin receptorblocking class ( losartan , irbesartan , olmesartan , valsartan , candesartan ; washout period allow ) , nelfinavir , etravirine . Subjects take nelfinavir etravirine exclude due possibility increase drug level via inhibition cytochrome P450 2C19 . Note 1 : Subjects require amifostine rituximab must aware increase risk orthostatic hypotension addition telmisartan . Any subject requiring lithium therapy study must lithium level monitor closely outside physician . All subject list medication provide documentation physician aware study protocol . Note 2 : Subjects take thiazolidinediones must stable dosing ( &gt; 12 week ) must agree refrain dose titration 12week study duration . Untreated hyperlipidemia : Subjects must willing abstain initiating therapy 12week study duration . Subjects stable ( &gt; 12 week ) lipidlowering regimen must willing remain current dose 12week study duration . Subjects undergoing treatment diabetes oral hypoglycemic agent must willing remain current dose insulinsensitizing agent ( metformin/biguanides ) 12week study duration . Titration diabetes ( except thiazolidinediones , see 4.2.3 ) medication permit . Screening laboratory value follow : ANC &lt; 750 cells/mm3 Hemoglobin &lt; 10 gm/dL Creatinine clearance &lt; 30 mL/min ( estimate CockcroftGault equation use ideal body weight ) AST ALT &gt; 3 time ULN Known , untreated , renal artery stenosis . Unstable coronary artery disease/angina , decompensated congestive heart failure , predict need cardiovascular surgery within study period . History intolerance member angiotensin receptor blocker class agent . Need ongoing potassium supplementation . Active , untreated opportunistic and/or AIDSdefining illness .</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2014</verification_date>
	<keyword>HIV</keyword>
	<keyword>Flow-mediated dialation ( FMD )</keyword>
	<keyword>Telmisartan</keyword>
	<keyword>Cardiovascular disease ( CVD )</keyword>
	<keyword>HIV+ men woman age &gt; 50 risk heart disease</keyword>
</DOC>